Targeted sequencing method for simultaneously detecting helicobacter pylori drug-resistant gene mutation sites

Through targeted sequencing methods and multiple PCR amplification reactions, the time and complexity of Helicobacter pylori resistance detection are solved, and the simultaneous detection of multiple drug-resistant genes is achieved, which improves detection efficiency and accuracy, and provides More reliable results.

CN119082333AInactive Publication Date: 2024-12-06THE SECOND AFFILIATED HOSPITAL OF HAINAN MEDICAL UNIV

Patent Information

Application Number
CN202411438684.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-15
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, Helicobacter pylori resistance detection takes time, is complex in operation, and cannot cover all possible complex structural variants of antibiotic resistance genotypes, making it difficult to provide patients with personalized treatment options.

Method used

Targeted sequencing method is adopted to form Primer Pool by designing specific primers for multiple drug-resistant genes, performing multiple PCR amplification reactions, and combining with the Illumina sequencing platform for library sequencing, achieving simultaneous detection of multiple drug-resistant genes.

Benefits of technology

Improve detection efficiency and accuracy, reduce false positive or false negative results, reduce costs, and provide more reliable drug resistance test results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to the technical field of molecular biological detection, and particularly discloses a targeted sequencing method for simultaneously detecting helicobacter pylori drug-resistant gene mutation sites, and the targeted sequencing method comprises the following steps: S1, extracting helicobacter pylori DNA; s2, breaking a helicobacter pylori genome, filling in, repairing and adding A; s3, linker connection and purification; s4, designing a specific primer of a to-be-detected region of the drug-resistant gene; s5, synthesizing a primer, and mixing to form Primer Pool; s6, carrying out multiple PCR (Polymerase Chain Reaction) amplification reaction and purification; s7, library quality inspection; s8, sequencing the library; according to the targeted sequencing method, specific primers of multiple drug-resistant genes are mixed to form Primer Pool, and then the Primer Pool is utilized to perform multiple PCR amplification reaction, so that the targeted sequencing method has the advantages of high efficiency, low cost and good accuracy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of molecular biological detection technology, and more specifically, to a targeted sequencing method for simultaneously detecting mutation sites of Helicobacter pylori resistance genes. Background Art

[0002] Helicobacter pylori ( Helicobacter pylori ) is a bacterium that widely infects the human gastric mucosa and is closely related to a variety of gastrointestinal diseases such as chronic gastritis, gastric ulcers, duodenal ulcers and gastric cancer. At present, the treatment of Helicobacter pylori infection mainly relies on antibiotic therapy. The antibiotics used mainly include amoxicillin, furazolidone, metronidazole, levofloxacin, clarithromycin, tetracycline, etc. However, with the popularization of antibiotic use, the emergence of drug-resistant Helicobacter pylori strains has become a global public health problem.

[0003] The detection of drug resistance of Helicobacter pylori mainly relies on bacterial culture and drug sensitivity testing, which are time-consuming, complicated to operate, and require high experimental conditions. In addition, this traditional method of drug resistance detection cannot provide information about the molecular mechanism of drug resistance development, so it is difficult to provide patients with personalized treatment plans in clinical practice. The existing technology uses molecular biological methods to detect the drug resistance of Helicobacter pylori, mainly including: PCR gel electrophoresis, fluorescent quantitative PCR, first-generation sequencing technology, etc. Compared with traditional technologies, the existing technology is faster and the results are more accurate, but it still faces the problem that the detection throughput of a detection reaction is limited and cannot cover all possible complex structural variants of antibiotic resistance genotypes.

[0004] Based on the above statements, the present application provides a targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites. Summary of the invention

[0005] In order to solve the problems in the detection of Helicobacter pylori resistance, that is, traditional technology is time-consuming, complicated to operate, and has high requirements on experimental conditions, and the detection throughput of a detection reaction in the existing technology is limited and cannot cover all possible complex structural variants of antibiotic resistance genotypes, the present application provides a targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites.

[0006] The present application provides a targeted sequencing method for simultaneously detecting mutation sites of Helicobacter pylori resistance genes, using the following technical solutions: A targeted sequencing method for simultaneously detecting mutation sites of Helicobacter pylori drug-resistant genes, comprising the following steps: S1. extraction of Helicobacter pylori DNA; S2. interruption of the Helicobacter pylori genome and blunting repair and A addition; S3. adapter connection and purification; S4. design of specific primers for the drug-resistant gene test region; S5 synthesis of primers, mixing to form a Primer Pool; S6. multiplex PCR amplification reaction and purification; S7. library quality inspection; S8. library sequencing.

[0007] Preferably, the source of the Helicobacter pylori is a gastric mucosal sample or a stool sample.

[0008] Preferably, the purification in step S3 and step S6 adopts QuarAcces Hyper Pure beads purification method.

[0009] Preferably, the drug-resistant genes in step S4 are PBP1, porD, oorD, rdxA, gyrA, 23S rRNA, and 16S rRNA.

[0010] Preferably, the step of mixing primers to form a Primer Pool in step S5 is: first synthesizing the primers designed in step S4, diluting the concentration of the synthesized primers to 8-12 μM, then adding samples according to the mixing ratio, and vortexing for 15-30 seconds to mix evenly.

[0011] Preferably, the mixing ratio of the primers is PBP1:porD:oorD:rdxA:gyrA:23S rRNA:16S rRNA=0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2.

[0012] Preferably, the library quality inspection in step S6 uses an Agilent 2100 or 4200 instrument to detect the length of the DNA library fragments, and the length of the fragments that meet the library sequencing requirements is 200-400 bp.

[0013] Preferably, the library quality check in step S6 uses QubitBR to measure the concentration, and the concentration that meets the library sequencing is 5-50nmol / μl.

[0014] Preferably, the library sequencing in step S7 adopts one of the HiSeq 3000 / 4000, NextSeq, X-Ten or NovaSeq sequencing systems in the Illumina sequencing platform.

[0015] In summary, this application has the following beneficial effects: The targeted sequencing method of the present application adopts a method of mixing specific primers of multiple drug-resistant genes to form a Primer Pool, and then using the Primer Pool to perform multiple PCR amplification reactions. High efficiency: Multiplex PCR can simultaneously amplify multiple different nucleic acid fragments in the same reaction system, and can detect multiple drug-resistant genes at the same time, thereby greatly improving the detection efficiency. Cost saving: Multiplex PCR reduces the reagent, time and labor costs required for multiple PCRs alone, and has high economic benefits. High accuracy: By detecting multiple drug-resistant genes at the same time, it reduces false positive or false negative results caused by insufficient detection of a single gene, thereby improving the reliability of the test. DETAILED DESCRIPTION

[0016] The present application is further described in detail below with reference to the embodiments.

[0017] Example 1-6 provides a targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites.

[0018] Example 1 Bacterial DNA extraction 1. Transfer 1.5 ml of bacterial culture medium to a 2 ml centrifuge tube, centrifuge at 10,000 × g for 1 min, collect the bacterial pellet, and discard the culture medium; 2. Add 220µl Buffer STEPlus, 30µl Lysozyme and 10µl RNaseA to the bacterial pellet, vortex for 30s to fully resuspend the bacteria, and let stand at room temperature for 15min to obtain a bacterial resuspension; 3. Add 250µl Buffer DL and 10µl ProteinaseK to the bacterial resuspension, vortex for 30s to mix, and react in a 70℃ water bath for 10min to obtain bacterial lysate; 4. Centrifuge the bacterial lysate from step 3 at 10,000 × g for 3 min, remove the pelleted material, and transfer the supernatant to a new 2 ml centrifuge tube; Add 250µl of anhydrous ethanol, vortex mix for 15s, and pipette 5 times to break up the flocculent precipitate; put HiPure DNA Mini Column I in a new 2ml collection tube, transfer the mixed solution in step 5 to HiPureDNA Mini Column I, and centrifuge at 10,000×g for 1min; discard the filtrate, put HiPure DNA Mini Column I back into the collection tube, add 500µl of Buffer GW1 diluted with anhydrous ethanol to HiPure DNA Mini Column I, and centrifuge at 10,000×g for 1min; discard the filtrate, put HiPure DNA Mini Column I back into the collection tube, add 600µl of Buffer GW2 diluted with anhydrous ethanol to HiPureDNA Mini Column I, and centrifuge at 10,000×g for 1min; discard the filtrate, put HiPure DNA Mini Column I back into the collection tube, and add 600µl of Buffer GW2 diluted with anhydrous ethanol to HiPureDNA Mini Column I, and centrifuge at 10,000×g for 1min; I was put back into the collection tube and centrifuged at 10,000×g for 2 minutes; 10. Preheat BufferAE to 70℃, put HiPure DNA Mini Column I in step 9 into a new 1.5ml centrifuge tube, add 50µl BufferAE to the center of HiPure DNA Mini Column I membrane, let it stand at room temperature for 3 minutes, and centrifuge at 10,000×g for 1 minute to obtain the required bacterial DNA.

[0019] Example 2 Genome interruption and fill-in repair Place DNA Frag Enzyme and End Repair-A Tailing Enzyme Mix on ice to melt, flick with fingers to mix, place DNA Frag-A Tailing Buffer and DNA Frag-A Tailing Enhancer on ice to melt, and vortex for 2 seconds.

[0020] First, the bacterial DNA in Example 1 was premixed with DNA Frag-A Tailing Buffer and DNA Frag-A Tailing Enhancer according to the reaction system in Table 1. After being mixed by pipetting for 7 times, DNA Frag Enzyme and End Repair-A Tailing Enzyme Mix were added according to the reaction system in Table 1. The mixed sample was centrifuged for 3 seconds, transferred to a precooled PCR instrument, the temperature of the hot cover was set to 70°C, and the PCR reaction program in Table 2 was run.

[0021] Table 1 Reaction system

[0022] Table 2 Reaction procedure

[0023] Example 3 Adapter ligation and purification 1. Dilution of Adaptor (IL-UDI-Y1-96): Measure the concentration of the bacterial DNA extracted in Example 1, dilute the adapter mixture with nuclease-free water according to the dilution ratio in Table 3. When the concentration of bacterial DNA is 10 ng / µL, 1 µL of adapter mixture + 9 µL of nuclease-free water is diluted to a 10-fold diluted adapter mixture. When the concentration of bacterial DNA is less than 1 ng / µL, a gradient dilution method is used to ensure the accuracy of the concentration. First dilute 10 times, then use the diluent plus nuclease-free water to make another 10-fold dilution.

[0024] Table 3

[0025] Table 4 Reaction system

[0026] 2. Run the PCR reaction program in Example 2 to the reaction product of the 4°C holding step, take out, add samples according to the reaction system in Table 4, and react according to the PCR reaction system in Table 5.

[0027] Table 5 Reaction procedure

[0028] 3. Incubate QuarAcces Hyper Pure beads at room temperature for 30 minutes. Add 64µl of QuarAcces Hyper Pure beads to the PCR reaction product in step 2, vortex for 5 seconds, mix well, let stand at room temperature for 5 minutes, place on a magnetic stand to clarify, and discard the supernatant.

[0029] 4. Add 200 µL of 80% ethanol aqueous solution, let stand at room temperature for 30 seconds, discard the supernatant, and repeat once. Centrifuge for 15 seconds, use a 10 µL pipette to suck out excess ethanol, and let stand at room temperature for 5 minutes.

[0030] 5. Add 17 µL of nuclease-free water to resuspend the magnetic beads, vortex for 3 seconds to mix evenly, let stand at room temperature for 2 minutes, place on a magnetic stand to clarify, aspirate the supernatant, and transfer to a new PCR tube.

[0031] Example 4 Primer design and primer mixing to form a Primer Pool For amoxicillin ( PBP1 )、Furazolidone( porD,oorD )、Metronidazole( rdxA )、Levofloxacin( gyrA )、clarithromycin( 23S rRNA ),tetracycline( 16S rRNA ) Design specific primers for the test region of the drug-resistant gene resistance site, as shown in Table 6.

[0032] Table 6

[0033] The above primers were synthesized according to the primer sequences, and the synthesized primers were diluted to 10 μM and then mixed to form a Primer Pool. The mixing ratio of the primers in the Primer Pool was PBP1 : porD : oorD : rdxA : gyrA : 23S rRNA : 16S rRNA =1:1:1:1:1:1:1:1. After adding the sample according to the mixing ratio, vortex for 25 seconds to mix evenly to obtain the PrimerPool.

[0034] Example 5 Multiplex PCR amplification and purification 1. The product of Example 3 was added according to the reaction system in Table 7, vortexed for 5 seconds to mix evenly, and reacted according to the PCR conditions in Table 8.

[0035] Table 7 Reaction system

[0036] Table 8 Reaction procedure

[0037] 2. After the PCR reaction is completed, add 40 µL of QuarAcces Hyper Pure beads to the PCR tube, vortex for 5 seconds to mix evenly, leave at room temperature for 5 minutes, place on a magnetic stand to clarify, and discard the supernatant.

[0038] 3. Add 200 µL of 80% ethanol aqueous solution, let stand at room temperature for 30 seconds, discard the supernatant, and repeat once. Centrifuge for 15 seconds, use a 10 µL pipette to suck out excess ethanol, and let stand at room temperature for 3 minutes.

[0039] 4. Add 20 µL of nuclease-free water to resuspend the magnetic beads, vortex for 5 seconds to mix evenly, leave at room temperature for 2 minutes, place on a magnetic stand to clarify, aspirate the supernatant, and transfer to a new PCR tube to obtain the final DNA library.

[0040] Example 6 Library quality inspection and library sequencing The DNA library samples were quality checked using an Agilent Bioanalyzer 4200 instrument. The reagent required for 4200 was High Sensitivity D1000, and the peak value obtained by the quality check was 250-350bp.

[0041] The DNA library samples were quality checked using the QubitBR instrument at a concentration of 48.35 nmol / μl.

[0042] After the library quality inspection was qualified, the NextSeq sequencing system of the Illumina sequencing platform was used for sequencing, and the library was sequenced in 2*150 sequencing mode.

[0043] After library sequencing, a fastq format file was generated. By analyzing the sequencing results and mutation status, the results were obtained as shown in Table 9.

[0044]

[0045] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.

Claims

1. A targeted sequencing method for simultaneously detecting mutation sites of Helicobacter pylori resistance genes, characterized in that: The following steps are involved: S1. Extraction of Helicobacter pylori DNA; S2. Helicobacter pylori genome interruption and repair and A addition; S3. Adapter ligation and purification; S4. Design specific primers for the region of drug resistance gene to be tested; S5 synthesize primers and mix them to form a Primer Pool; S6. Multiplex PCR amplification reaction and purification; S7. Library quality inspection; S8. Library sequencing.

2. A targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites according to claim 1, characterized in that: The source of the Helicobacter pylori is a gastric mucosal sample or a feces sample.

3. A targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites according to claim 1, characterized in that: The purification in step S3 and step S6 adopts QuarAcces Hyper Pure beads magnetic bead purification method.

4. A targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites according to claim 1, characterized in that: The drug-resistant genes in step S4 are PBP1, porD, oorD, rdxA, gyrA, 23S rRNA, and 16S rRNA.

5. The targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites according to claim 1, characterized in that: The step of mixing primers to form a Primer Pool in step S5 is as follows: first synthesizing the primers designed in step S4, diluting the concentrations of the synthesized primers to 8-12 μM, then adding samples according to the mixing ratio, and vortexing for 15-30 seconds to mix evenly.

6. A targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites according to claim 5, characterized in that: The mixing ratio of the primers is PBP1:porD:oorD:rdxA:gyrA:23S rRNA:16S rRNA=0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.

2.

7. A targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites according to claim 1, characterized in that: In step S6, the quality inspection of the library is performed using an Agilent 2100 or 4200 instrument to detect the length of the DNA library fragments, and the length of the fragments that meet the requirements for library sequencing is 200-400 bp.

8. A targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites according to claim 1, characterized in that: In step S6, the library quality check uses QubitBR to measure the concentration, and the concentration that meets the library sequencing is 5-50nmol / μl.

9. A targeted sequencing method for simultaneously detecting Helicobacter pylori resistance gene mutation sites according to claim 1, characterized in that: The library sequencing in step S7 adopts one of the HiSeq 3000 / 4000, NextSeq, X-Ten or NovaSeq sequencing systems in the Illumina sequencing platform.

Citation Information

Patent Citations

  • Miseq sequencing method for detecting helicobacter pylori gene and drug metabolism type

    CN107236788A

  • Illumina sequencing technology based kit and method for detecting hepatitis B typing and multi-drug resistant sites

    CN109609694A

  • Kit and method for detecting genes related to individualized medication for depression

    CN110157793A

  • Method and kit for typing detection of drug resistance of helicobacter pylori in oral cavity

    CN112760391A

  • 16S rDNA library construction method, 16S rDNA library and application

    CN114318552A

Cited By

  • Method for detecting drug-resistant mutation of helicobacter pylori 23SrRNA gene and application of method

    CN119899905A

  • Targeted sequencing method for multi-site drug-resistant gene mutation detection of helicobacter pylori

    CN121931229A